Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
3.770
-0.050 (-1.31%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Cytek Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -6.02 | -12.15 | 2.58 | 3.05 | 19.41 | Upgrade
|
| Depreciation & Amortization | 10.49 | 9.23 | 5.66 | 1.24 | 0.6 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.06 | 0.01 | - | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | 0.28 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -5.21 | -6.66 | -0.08 | - | - | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | -0.04 | - | Upgrade
|
| Stock-Based Compensation | 26.85 | 22.05 | 16.6 | 6.59 | 0.61 | Upgrade
|
| Provision & Write-off of Bad Debts | -0.06 | 0.27 | 0.1 | - | 0.18 | Upgrade
|
| Other Operating Activities | -8.43 | 3.05 | 2.84 | 2.15 | 1.89 | Upgrade
|
| Change in Accounts Receivable | -5.43 | -7.33 | -19.74 | -12.37 | 0.33 | Upgrade
|
| Change in Inventory | 14.76 | 4.29 | -17.65 | -7.07 | -5.7 | Upgrade
|
| Change in Accounts Payable | 2.58 | -1.78 | 1.86 | -0.26 | -0.06 | Upgrade
|
| Change in Unearned Revenue | 3.74 | 6.52 | 9.41 | 10.01 | 2.38 | Upgrade
|
| Change in Other Net Operating Assets | -7.93 | -12.2 | -13.8 | 1.03 | -4.49 | Upgrade
|
| Operating Cash Flow | 25.38 | 5.28 | -12.23 | 4.63 | 15.16 | Upgrade
|
| Operating Cash Flow Growth | 380.57% | - | - | -69.45% | - | Upgrade
|
| Capital Expenditures | -3.53 | -4.65 | -9.75 | -4.36 | -1.55 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.29 | - | - | - | - | Upgrade
|
| Cash Acquisitions | -0.47 | -45.13 | - | -16.63 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.2 | -0.18 | -0.12 | - | - | Upgrade
|
| Investment in Securities | -79.06 | -43.94 | -46.04 | - | - | Upgrade
|
| Investing Cash Flow | -82.97 | -93.89 | -55.91 | -20.99 | -1.55 | Upgrade
|
| Short-Term Debt Issued | 4.18 | - | - | - | 4.08 | Upgrade
|
| Long-Term Debt Issued | - | - | 2.98 | - | - | Upgrade
|
| Total Debt Issued | 4.18 | - | 2.98 | - | 4.08 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | -2.77 | -1.31 | Upgrade
|
| Long-Term Debt Repaid | -0.56 | -0.57 | -0.05 | - | - | Upgrade
|
| Total Debt Repaid | -0.56 | -0.57 | -0.05 | -2.77 | -1.31 | Upgrade
|
| Net Debt Issued (Repaid) | 3.62 | -0.57 | 2.93 | -2.77 | 2.77 | Upgrade
|
| Issuance of Common Stock | 2.72 | 3.32 | 2.79 | 216.33 | 0.17 | Upgrade
|
| Repurchase of Common Stock | -22.17 | -44.57 | -0.21 | - | - | Upgrade
|
| Financing Cash Flow | -15.82 | -41.81 | 5.51 | 213.56 | 122.61 | Upgrade
|
| Foreign Exchange Rate Adjustments | 4.53 | -1.45 | -2.49 | 1.3 | -0.59 | Upgrade
|
| Net Cash Flow | -68.89 | -131.87 | -65.12 | 198.5 | 135.63 | Upgrade
|
| Free Cash Flow | 21.85 | 0.63 | -21.98 | 0.27 | 13.61 | Upgrade
|
| Free Cash Flow Growth | 3352.45% | - | - | -98.05% | - | Upgrade
|
| Free Cash Flow Margin | 10.90% | 0.33% | -13.40% | 0.21% | 14.66% | Upgrade
|
| Free Cash Flow Per Share | 0.17 | 0.01 | -0.16 | 0.00 | 0.42 | Upgrade
|
| Cash Income Tax Paid | 3.83 | 5.31 | 10.39 | 2.86 | 2.07 | Upgrade
|
| Levered Free Cash Flow | 36.25 | -1.34 | -23.76 | -6.21 | 4.97 | Upgrade
|
| Unlevered Free Cash Flow | 36.25 | -0.04 | -22.15 | -5.12 | 5.18 | Upgrade
|
| Change in Net Working Capital | -17.1 | 9.09 | 33.41 | 14.31 | 3.02 | Upgrade
|
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.